Back

AstraZeneca COPD trial shows tozorakimab cuts flare-ups by 29% to 34%

Verifying
  • AstraZeneca reported positive phase III results for tozorakimab in COPD
  • Tozorakimab reduced the reported measure by 29% to 34%
  • Former smokers recorded the strongest reduction in flare-ups
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.